The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting provides a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy.
The Annual Meeting consists of cutting-edge research presentations by experts in the field, both oral and poster abstract presentations, and ample opportunity for structured and informal discussions, including important networking opportunities. In addition, the meeting includes updates on major national and international initiatives coming from academia, government and industry, as well as important society projects.
Following SITC’s tradition of collaborating to advance the field, SITC 2019 features sessions collaboratively-developed with reputable organizations whose missions complement and align with that of SITC’s. The meeting will conclude with the Hot Topic Symposium, an in-depth look at an emerging topic in the field.
The audience includes U.S. and international researchers, regulators and healthcare professionals involved in cancer research and clinical care. This includes, but is not limited to basic, translational and clinical researchers; postdoctoral fellows; oncologists; registered nurses; nurse practitioners; pharmacists; payers; and other allied health professionals.
34th Annual Meeting Organizers
- Ana Carrizosa Anderson, PhD – Harvard Medical School
- Marianne Davies, DNP, AOCNP – Yale School of Nursing
- Stefani Spranger, PhD – Koch Institute for Integrative Cancer Research at MIT
- Ahmad A. Tarhini, MD, PhD – Emory University and Winship Comprehensive Cancer Center
Annual Program Committee
- Chair: Sandra Demaria, MD – Weill Cornell Medicine
- Davide Bedognetti, MD, PhD – Sidra Medical
- Patrick Hwu, MD – The University of Texas MD Anderson Cancer Center
- Krista Rubin, MS, FNP-BC – Massachusetts General Hospital
- Dario A.A. Vignali, PhD – University of Pittsburgh
Upon completion of this meeting, participants will be able to:
Summarize and integrate the most recent advances in tumor immunology and cancer immunotherapy into basic, clinical and translational research
Analyze cutting-edge clinical trials to incorporate new research and techniques into clinical applications for cancer immunotherapy
Describe immune regulatory pathways that restrict and enhance immunity to tumor antigens, and identify respective targets for therapeutic intervention
34th Annual Meeting Schedule
To view the Annual Meeting's full schedule, please click here
Annual Meeting is supported in part by grants from AbbVie, AstraZeneca Pharmaceuticals, LP, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Fluidigm, Gilead Sciences, Inc., Incyte Corporation, Janssen Research & Development, LLC, Merck & Co., Inc., NanoString Technologies, Novartis Pharmaceuticals, Pfizer, Inc., and TESARO, Inc. (as of September 8, 2019)